These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6293062)

  • 1. [Phase II study of 3 new nitrosoureas, 1 American (chlorozotocin) and 2 French (RFCNU and RPCNU)].
    Mathé G; Schein PS; De Vassal F; Serrou B; Imbach JL
    Sem Hop; 1982 Sep; 58(33):1867-71. PubMed ID: 6293062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preliminary results of phase I and II clinical trials of RFCNU, a new nitrosourea sugar derivative, in digestive tract tumours].
    Mathé G; Serrou B; Hayat M; De Vassal F; Misset JL; Schwarzenberg L; Machover D; Ribaud P; Belpomme D; Jasmin C; Musset M; Montero JL; Imbach JL
    Biomedicine; 1977 Nov; 27(8):294-7. PubMed ID: 339971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice.
    Hayat M; Bourut C; Chenu E; Montero JL; Imbach JL; MacDonald JS; Mathé G
    Cancer Chemother Pharmacol; 1979; 3(4):217-21. PubMed ID: 161207
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative analysis of the immunopharmacological properties of three new nitrosourea analogues: RPCNU, RFCNU and Chlorozotocin.
    Florentin I; Hayat M; Kiger N; Mathé G; Maral J; Imbach JL
    Int J Immunopharmacol; 1983; 5(3):201-10. PubMed ID: 6225736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the experimental antitumor activities of three nitrosourea derivatives chlorozotocin, RFCNU and CNCC encapsulated in liposomes with those in the free state.
    Maral R; Bourut C; Chenu E; Mathe G; Bernon R; Lussan C; Imbach JL; Schein P; Bothorel P
    Oncology; 1985; 42(2):122-8. PubMed ID: 3157909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytofluorometric analysis of the effects of new nitrosourea derivatives on proliferation of EMT 6 tumor cells "in vitro".
    Vlaeminck MN; Collyn-d'Hooghe M; Cappelaere P; Biserte G; Oiry J; Montero JL; Imbach JL
    Biomedicine; 1981 Mar; 35(1):27-9. PubMed ID: 7016209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplified pulmonary metastases of a rat rhabdomyosarcoma in response to nitrosourea treatment.
    Poupon MF; Pauwels C; Jasmin C; Antoine E; Lascaux V; Rosa B
    Cancer Treat Rep; 1984 May; 68(5):749-58. PubMed ID: 6233004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Logistic regression model of fotemustine toxicity combining independent phase II studies.
    Raymond E; Haon C; Boaziz C; Coste M
    Cancer; 1996 Nov; 78(9):1980-7. PubMed ID: 8909320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of three new nitrosourea analogs (CNCC, RFCNU and chlorozotocin) on in vivo destruction of L 1210 leukemia cells and on the immune response.
    Andrade Mena CE; Orbach-Arbouys S; Cosmatopoulos K; Mathé G
    Chemotherapy; 1986; 32(2):131-7. PubMed ID: 2938892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1985 Apr; 69(4):417-20. PubMed ID: 2859924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group.
    Mouridsen HT; Bramwell VH; Lacave J; Metz R; Vendrik C; Hild J; McCreanney J; Sylvester R
    Cancer Treat Rep; 1981; 65(5-6):509-11. PubMed ID: 6453646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the nitrosourea derivative rpcnu (ICIG 1163) on the development of Friend leukemia in mice.
    Larnicol N; Augery Y; Jasmin C; Montero JL; Imbach JL
    Biomedicine; 1977 May; 26(3):176-81. PubMed ID: 890012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of chlorozotocin in the treatment of advanced colorectal cancer.
    Lawton JO; Giles GR; Hall J; MacAdam A; Hall R; Matheson T; Bird G
    Cancer Treat Rep; 1981; 65(1-2):13-15. PubMed ID: 6452945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors.
    Silver BA; Barlock AL; Lippman ME; Anderson T; Fisher RI
    Cancer Treat Rep; 1982 May; 66(5):1229-30. PubMed ID: 6211231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of GANU and MCNU.
    Ogawa M
    Cancer Treat Rev; 1980 Dec; 7(4):197-203. PubMed ID: 6452200
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas].
    Wakui A
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1327-38. PubMed ID: 6223595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytostatic action of two nitrosoureas derived from cysteamine.
    Bourut C; Chenu E; Godenèche D; Madelmont JC; Maral R; Mathé G; Meyniel G
    Br J Pharmacol; 1986 Nov; 89(3):539-46. PubMed ID: 3801787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship of labeled molecules in the pharmacokinetic study of alkylating agents (chlorambucil, melphalan, mitoclomine) and glycosyl nitrosoureas (RFCNU and RPCNU)].
    Meyniel G; Godenech D
    Nouv Rev Fr Hematol (1978); 1979; Suppl():XXXIII-XXXV. PubMed ID: 545309
    [No Abstract]   [Full Text] [Related]  

  • 20. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.